Inhibitors of Type VI Sectretion in NIAID Priority Pathogens

$372,289U54FY2011AINIH

Harvard Medical School, Boston MA

Investigators

Linked publications & trials

Paper 38680558 Paper 37780364 Paper 37662211 Paper 37610224 Paper 34417313 Paper 33408184 Paper 33319995 Paper 32987745 Paper 32603593 Paper 32364380 Paper 32348107 Paper 31914414 Paper 31809018 Paper 30395379 Paper 29937406 Paper 28871080 Paper 28781126 Paper 28706631 Paper 28698673 Paper 28658630 Paper 28400473 Paper 28034743 Paper 27992879 Paper 27911388 Paper 27672120 Paper 27579370 Paper 27572444 Paper 27539858 Paper 27539384 Paper 27336950 Paper 27193679 Paper 27105280 Paper 27101010 Paper 26980837 Paper 26919416 Paper 26912630 Paper 26910435 Paper 26872864 Paper 26840427 Paper 26807441 Paper 26747103 Paper 26740390 Paper 26707217 Paper 26701099 Paper 26619249 Paper 26613408 Paper 26549784 Paper 26510153 Paper 26473364 Paper 26396190 Paper 26392509 Paper 26216419 Paper 26195743 Paper 26192320 Paper 26191658 Paper 26178180 Paper 26144317 Paper 26078454 Paper 26041296 Paper 26039584 Paper 25987613 Paper 25866377 Paper 25851602 Paper 25778700 Paper 25641385 Paper 25599080 Paper 25583731 Paper 25578459 Paper 25564615 Paper 25479384 Paper 25404023 Paper 25317832 Paper 25313218 Paper 25250705 Paper 25232009 Paper 25229405 Paper 25211455 Paper 25171292 Paper 25170904 Paper 25144274 Paper 25142600 Paper 25139905 Paper 25060816 Paper 25053799 Paper 25019406 Paper 24958711 Paper 24933423 Paper 24919153 Paper 24907552 Paper 24837431 Paper 24831788 Paper 24829348 Paper 24828915 Paper 24828532 Paper 24815030 Paper 24696346 Paper 24687512 Paper 24684906 Paper 24683195 Paper 24667709

Abstract

A number of pathogenic microorganisms, including, several NIAID Priority Pathogens, secrete virulence factors utilizing a novel pathway referred to as the type VI secretion system (T6SS). The main objective of this project is to develop inhibitors of T6SS that could lead to a new class of antimicrobial agents. Burkholderia thailandensis will be used to identify T6SS inhibitors compounds in a high throughput screen and these will be tested for interference with secretion in several category A-C select agents, including Burkholderia pseudomallei and Burkholderia mallei, causative agents of melioidosis and glanders, respectively. The candidate inhibitors of T6SS and their structural derivatives will be used in subsequent studies, which include demonstration of their efficacy in an animal model of melioidosis. The T6SS components, targeted by the active compounds will be identified. The work proposed in this project represents a logical pre-clinical development strategy for therapeutic agents targeting several agents of biological warfare and bioterrorism.

View original record on NIH RePORTER →